vs
Side-by-side financial comparison of BayCom Corp (BCML) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $25.9M, roughly 1.1× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -5.9%, a 32.3% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs 4.6%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
BCML vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $27.5M |
| Net Profit | $6.9M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 36.6% | 23.5% |
| Net Margin | 26.5% | -5.9% |
| Revenue YoY | 9.4% | 4.6% |
| Net Profit YoY | 12.1% | 5.3% |
| EPS (diluted) | $0.63 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $27.5M | ||
| Q3 25 | $25.7M | $26.3M | ||
| Q2 25 | $24.7M | $25.8M | ||
| Q1 25 | $24.3M | $23.4M | ||
| Q4 24 | $23.7M | $26.3M | ||
| Q3 24 | $25.6M | $21.7M | ||
| Q2 24 | $23.8M | $20.2M | ||
| Q1 24 | $24.5M | $18.5M |
| Q4 25 | $6.9M | $-1.6M | ||
| Q3 25 | $5.0M | $-30.4M | ||
| Q2 25 | $6.4M | $-2.0M | ||
| Q1 25 | $5.7M | $-3.5M | ||
| Q4 24 | $6.1M | $-1.7M | ||
| Q3 24 | $6.0M | $-2.9M | ||
| Q2 24 | $5.6M | $-3.5M | ||
| Q1 24 | $5.9M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 36.6% | 23.5% | ||
| Q3 25 | 26.3% | 11.2% | ||
| Q2 25 | 35.3% | -0.1% | ||
| Q1 25 | 31.6% | -8.9% | ||
| Q4 24 | 34.2% | 18.6% | ||
| Q3 24 | 32.4% | 3.6% | ||
| Q2 24 | 31.9% | -14.3% | ||
| Q1 24 | 33.3% | -8.3% |
| Q4 25 | 26.5% | -5.9% | ||
| Q3 25 | 19.5% | -115.5% | ||
| Q2 25 | 25.8% | -7.8% | ||
| Q1 25 | 23.4% | -15.1% | ||
| Q4 24 | 25.9% | -6.5% | ||
| Q3 24 | 23.5% | -13.2% | ||
| Q2 24 | 23.6% | -17.4% | ||
| Q1 24 | 24.0% | -9.5% |
| Q4 25 | $0.63 | $-0.32 | ||
| Q3 25 | $0.46 | $-3.40 | ||
| Q2 25 | $0.58 | $-0.23 | ||
| Q1 25 | $0.51 | $-0.41 | ||
| Q4 24 | $0.55 | $-0.18 | ||
| Q3 24 | $0.54 | $-0.34 | ||
| Q2 24 | $0.50 | $-0.41 | ||
| Q1 24 | $0.51 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $338.6M | $5.9M |
| Total Assets | $2.6B | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $338.6M | $5.9M | ||
| Q3 25 | $334.3M | $6.1M | ||
| Q2 25 | $330.6M | $35.4M | ||
| Q1 25 | $329.3M | $36.7M | ||
| Q4 24 | $324.4M | $39.4M | ||
| Q3 24 | $321.7M | $39.8M | ||
| Q2 24 | $315.3M | $41.7M | ||
| Q1 24 | $314.2M | $43.3M |
| Q4 25 | $2.6B | $72.9M | ||
| Q3 25 | $2.6B | $71.1M | ||
| Q2 25 | $2.6B | $98.8M | ||
| Q1 25 | $2.6B | $96.4M | ||
| Q4 24 | $2.7B | $88.1M | ||
| Q3 24 | $2.6B | $88.5M | ||
| Q2 24 | $2.6B | $73.4M | ||
| Q1 24 | $2.6B | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $3.9M |
| Free Cash FlowOCF − Capex | $30.1M | $3.9M |
| FCF MarginFCF / Revenue | 116.2% | 14.0% |
| Capex IntensityCapex / Revenue | 6.7% | 0.3% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $3.9M | ||
| Q3 25 | $7.3M | $2.2M | ||
| Q2 25 | $6.4M | $2.7M | ||
| Q1 25 | $9.3M | $-2.0M | ||
| Q4 24 | $30.4M | $932.0K | ||
| Q3 24 | $9.6M | $2.1M | ||
| Q2 24 | $7.7M | $-1.4M | ||
| Q1 24 | $5.1M | $-1.6M |
| Q4 25 | $30.1M | $3.9M | ||
| Q3 25 | $6.2M | $1.1M | ||
| Q2 25 | $5.6M | $902.7K | ||
| Q1 25 | $9.1M | $-3.7M | ||
| Q4 24 | $28.7M | $859.9K | ||
| Q3 24 | $9.4M | $2.0M | ||
| Q2 24 | $7.4M | $-1.5M | ||
| Q1 24 | $3.9M | $-1.7M |
| Q4 25 | 116.2% | 14.0% | ||
| Q3 25 | 24.3% | 4.2% | ||
| Q2 25 | 22.8% | 3.5% | ||
| Q1 25 | 37.6% | -15.9% | ||
| Q4 24 | 121.1% | 3.3% | ||
| Q3 24 | 36.6% | 9.4% | ||
| Q2 24 | 31.2% | -7.3% | ||
| Q1 24 | 16.1% | -9.0% |
| Q4 25 | 6.7% | 0.3% | ||
| Q3 25 | 4.3% | 4.0% | ||
| Q2 25 | 3.0% | 6.8% | ||
| Q1 25 | 0.6% | 7.4% | ||
| Q4 24 | 7.2% | 0.3% | ||
| Q3 24 | 1.0% | 0.0% | ||
| Q2 24 | 1.0% | 0.3% | ||
| Q1 24 | 4.7% | 0.4% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
